comparemela.com

New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study

New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States ,Americans ,Dineshv Patel ,Corey Davis ,Scott Plevy ,Johnson ,Protagonist Therapeutics Inc ,Takeda Pharmaceuticals Co Ltd ,Network Of Companies ,Nasdaq ,Exchange Commission ,Protagonist Therapeutics ,New England Journal ,Psoriasis Area ,Severity Index ,Global Assessment ,Patient Reported Outcomes ,Psoriasis Symptoms ,Signs Diary ,Dermatology Life Quality Index ,Executive Vice President ,Therapeutic Head ,Private Securities Litigation Reform Act ,

comparemela.com © 2020. All Rights Reserved.